12:00 AM
 | 
Feb 25, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Lyxumia lixisenatide regulatory update

FDA accepted for review an NDA from Sanofi for lixisenatide to treat adults with Type II diabetes. The pharma submitted the NDA in December, but the PDUFA date is not disclosed. Earlier this month, the European Commission approved an MAA for...

Read the full 184 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >